C07K 2317/94
Stability
Official title: Stability, e.g. half-life, pH, temperature or enzyme-resistance
C07K2317/94 (Stability) appears on 3,281 US grants and 6,764 published applications in this corpus.
Search patents in C07K- Granted patents
- 3,281
- Published applications
- 6,764
- Assignees
- 1,542
- Inventors
- 10,906
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 1 | 3 |
| 2004 | 1 | 5 |
| 2005 | 1 | 5 |
| 2006 | 2 | 13 |
| 2007 | 1 | 9 |
| 2008 | 2 | 15 |
| 2009 | 5 | 33 |
| 2010 | 5 | 42 |
| 2011 | 19 | 73 |
| 2012 | 21 | 106 |
| 2013 | 44 | 165 |
| 2014 | 90 | 262 |
| 2015 | 119 | 260 |
| 2016 | 176 | 380 |
| 2017 | 235 | 432 |
| 2018 | 212 | 395 |
| 2019 | 265 | 487 |
| 2020 | 310 | 482 |
| 2021 | 293 | 581 |
| 2022 | 282 | 549 |
| 2023 | 283 | 583 |
| 2024 | 323 | 724 |
| 2025 | 345 | 651 |
| 2026 | 246 | 509 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Enhancement of immune response with oral immunoglobulin polypeptides6 Oct 2026US 12,752,004 B2Iogenetics, LLC
- Aggrecan binding immunoglobulins6 Oct 2026US 12,753,224 B2Ablynx N. V.
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Process for preparing immunoglobulin compositions29 Sep 2026US 12,747,282 B2Biotest GmbH & Co. KGaA
- Liquid pharmaceutical composition comprising an anti-il-6 receptor antibody22 Sep 2026US 12,742,014 B2Fresenius Kabi Deutschland GmbH
- Methods for treatment using anti-alpha4beta7 antibody8 Oct 2026US 2026/0306636 A1Takeda Pharmaceutical Company Limited
- Radiolabeled met binding proteins for immuno-pet imaging8 Oct 2026US 2026/0306682 A1Regeneron Pharmaceuticals, Inc.
- Methods of treating inflammatory diseases8 Oct 2026US 2026/0308246 A1Boehringer Ingelheim International GmbH
- Multi-domain molecules8 Oct 2026US 2026/0308260 A1Immunocore Limited
- Antibody that binds to c3bbb8 Oct 2026US 2026/0308278 A1Hoffmann-La Roche Inc.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics940US 8,008,449 B2Medarex, Inc. · 2011
- Molecules with extended half-lives, compositions and uses thereof342US 7,083,784 B2MedImmune, LLC · 2006
- Human antibodies that bind human IL-12 and methods for producing300US 6,914,128 B1Abbott GmbH & Co. KG · 2005
- Anti-PD1 antibodies and their use as therapeutics and diagnostics285US 8,735,553 B1BeiGene, Ltd. · 2014
- Monoclonal antibodies to programmed death 1 (PD-1)233US 8,779,105 B2Medarex, Inc. · 2014